Comparison between Concord Biotech IPO and EbixCash IPO.
Concord Biotech IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while EbixCash IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Concord Biotech IPO is up to ₹1,550.52 Cr whereas the issue size of the EbixCash IPO is up to ₹6,000.00 Cr. The final issue price of Concord Biotech IPO is ₹741.00 per share and of EbixCash IPO is .
| Concord Biotech IPO | EbixCash IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ₹705.00 per share | |
| Issue Price (Upper) | ₹741.00 per share | |
| Issue Price (Final) | ₹741.00 per share | |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ₹70.00 per share | |
| Market Lot Size | 20 shares | |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹6,000.00 Cr |
| OFS Issue Size | 2,09,25,652 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹1,550.52 Cr | up to ₹0.00 Cr |
| Issue Size Total | 2,09,25,652 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹1,550.52 Cr | up to ₹6,000.00 Cr |
Concord Biotech IPO opens on Aug 04, 2023, while EbixCash IPO opens on . The closing date of Concord Biotech IPO and EbixCash IPO is Aug 08, 2023, and , respectively.
| Concord Biotech IPO | EbixCash IPO | |
|---|---|---|
| Anchor Bid Date | Aug 03, 2023 | |
| Issue Open | Aug 04, 2023 | |
| Issue Close | Aug 08, 2023 | |
| Basis Of Allotment (Tentative) | Aug 11, 2023 | |
| Initiation of Refunds (Tentative) | Aug 14, 2023 | |
| Credit of Share (Tentative) | Aug 17, 2023 | |
| Listing date (Tentative) | Aug 18, 2023 | |
| Anchor Lockin End date 1 | Sep 10, 2023 | |
| Anchor Lockin End date 2 | Nov 09, 2023 |
Concord Biotech IPO P/E ratio is 32.29, as compared to EbixCash IPO P/E ratio of .
| Concord Biotech IPO | EbixCash IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
|
Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 44.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 44.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 32.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹7752.06 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 20.06 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 24.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹20.79 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Concord Biotech IPO Retail Individual Investors (RII) are offered 73,20,479 shares while in EbixCash IPO retail investors are offered 73,20,479 shares. Qualified Institutional Buyers (QIB) are offered 41,83,130 shares in Concord Biotech IPO and in EbixCash IPO.
| Concord Biotech IPO | EbixCash IPO | |
|---|---|---|
| Anchor Investor Reservation | 62,74,695 shares | |
| Market Maker Reservation | ||
| QIB | 41,83,130 shares | |
| NII | 31,37,348 shares | |
| RII | 73,20,479 shares | |
| Employee | 10,000 shares | |
| Others | ||
| Total | 2,09,25,652 shares |
Concord Biotech IPO subscribed 17.41x in total, whereas EbixCash IPO subscribed .
| Concord Biotech IPO | EbixCash IPO | |
|---|---|---|
| QIB (times) | 67.67x | |
| NII (times) | 16.99x | |
| Big NII (times) | 19.30x | |
| Small NII (times) | 12.37x | |
| RII (times) | 3.78x | |
| Employee (times) | 24.48x | |
| Other (times) | ||
| Total (times) | 17.41x |
